Patents Assigned to Novartis AG
  • Formulations of (S)-3-amino-6-methoxy-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide
    Patent number: 11865109
    Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating bronchiectasis, chronic obstructive pulmonary disorder, cystic fibrosis, chronic bronchitis or asthma comprising administering to a subject in need thereof a therapeutically effective amount of a compound or pharmaceutical composition described herein.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: January 9, 2024
    Assignee: NOVARTIS AG
    Inventors: Vivek Dubey, Rohit Lowalekar, Paulo G. Santos, Hubert Thoma, Xianbin Tian
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20240002843
    Abstract: The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.
    Type: Application
    Filed: October 13, 2022
    Publication date: January 4, 2024
    Applicants: Novartis AG, Intellia Therapeutics, Inc.
    Inventors: Anthony Edward BOITANO, Michael COOKE, Lloyd B. KLICKSTEIN, Reynald LESCARBEAU, Craig Stephen MICKANIN, Kabungo MULUMBA, Seshidhar Reddy POLICE, Jennifer SNEAD, Susan C. STEVENSON, Morag STEWART, Yi YANG
  • Humanization of rabbit antibodies using a universal antibody framework
    Patent number: 11858981
    Abstract: The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: January 2, 2024
    Assignee: NOVARTIS AG
    Inventors: Leonardo Borras, David Urech
  • Compositions and methods for immunooncology
    Patent number: 11851659
    Abstract: The present disclosure is directed to genome editing systems, reagents and methods for immunooncology.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: December 26, 2023
    Assignees: Novartis AG, Intellia Therapeutics, Inc.
    Inventors: Jennifer Brogdon, Ming-Wei Chen, Hyungwook Lim, Yi Yang, Morag Stewart, Sarah Hesse
  • Method for preparing granules
    Patent number: 11844864
    Abstract: A method for preparing granules. A slurry containing solid API powder particles dispersed in a liquid is prepared. The slurry is fed to a granulator and mixed with a dry base powder within the granulator in order to produce a slurry/base powder mixture. The slurry/base powder mixture produced within the granulator is dried in order to obtain granules containing the solid API particles and the base powder.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: December 19, 2023
    Assignee: Novartis AG
    Inventors: Markus Krumme, Hans De Waard, Klaus-Peter Moll, Adrian Schmidt, Julien Taillemite
  • 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
    Patent number: 11833142
    Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ra, Rb, Rx, R1, R2, X2, and q are as defined herein, and methods of making and using same.
    Type: Grant
    Filed: October 4, 2021
    Date of Patent: December 5, 2023
    Assignee: Novartis AG
    Inventors: Rohan Eric John Beckwith, Simone Bonazzi, Artiom Cernijenko, Fupeng Ma, Nathaniel F. Ware
  • CKIT antibody drug conjugates
    Patent number: 11833215
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: December 5, 2023
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Dylan Daniel, Catrin Finner, Bernhard Hubert Geierstanger, Thomas Huber, William Mallet, Matthew John Meyer, Weijia Ou, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette
  • Method of treating structural and/or functional cardiac abnormalities by administering an anti-ActRII receptor antibody
    Patent number: 11834508
    Abstract: The disclosure relates to novel uses and methods for preventing and/or treating heart disease, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an ActRII receptor antibody, such as the bimagrumab antibody.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: December 5, 2023
    Assignees: Novartis AG, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Anthony Rosenzweig, Jason D. Roh, David J. Glass
  • Antibody molecules to PD-1 and uses thereof
    Patent number: 11827704
    Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: November 28, 2023
    Assignees: Novartis AG, DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • 2-azaspiro[3.4]octane derivatives as M4 agonists
    Patent number: 11820778
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Grant
    Filed: August 8, 2022
    Date of Patent: November 21, 2023
    Assignee: NOVARTIS AG
    Inventors: Amy Calhoun, Xin Chen, Kevin Matthew Gardinier, Edward Charles Hall, Keith Jendza, Nancy Labbe-Giguere, James Neef, Daniel Steven Palacios, Ming Qian, Michael David Shultz, Christopher G. Thomson, Kate Yaping Wang, Fan Yang
  • Micro-droplet delivery device and methods
    Patent number: 11819453
    Abstract: Micro-droplet delivery devices and methods are described where the device may comprise a piezoelectric actuator having a piezoelectric chip that is operatively coupled to a drug package under a preloading force. The actuator is configured to generate an acoustic pressure within the drug package to dispense droplets of an agent from an aperture, e.g., to the corneal surface of the eye. The piezoelectric actuator can be coupled or decoupled from the drug package.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: November 21, 2023
    Assignee: Novartis AG
    Inventor: Yehuda Ivri
  • Antiviral Pyrazolopiridinone Compounds
    Publication number: 20230365511
    Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.
    Type: Application
    Filed: February 6, 2023
    Publication date: November 16, 2023
    Applicants: Novartis AG, Gilead Sciences, Inc.
    Inventors: Zef Konst, Yipin Lu, Robert Joseph Moreau, Naomi Samadara Rajapaksa, Galen Shearn-Nance, David Charles Tully, Michael Robert Turner, Joseph Michael Young, Qian Zhao, Britton K. Corkey, Samuel E. Metobo
  • Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders
    Patent number: 11813306
    Abstract: The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, and X3 are described herein.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: November 14, 2023
    Assignee: Novartis AG
    Inventors: Karin Briner, Brian Addison Dechristopher, Alec Nathanson Flyer, Andrei Alexandrovich Golosov, Philipp Grosche, Eugene Yuejin Liu, Justin Yik Ching Mao, Lauren Gilchrist Monovich, Tajesh Jayprakash Patel, Liansheng Su, Lihua Yang, Rui Zheng
  • MODIFIED RELEASE FORMULATION
    Publication number: 20230355582
    Abstract: Drug products in the form of modified release formulations comprising the drug substance (-)-(3aR,45,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester (AFQ056), as well as processes for making such drug products are provided. The drug products are useful in treating patients with Parkinson's disease and exhibiting L-dopa induced dyskinesia.
    Type: Application
    Filed: July 20, 2023
    Publication date: November 9, 2023
    Applicant: NOVARTIS AG
    Inventors: Bruno GALLI, Jean-Marie GLANTZMANN, Arnaud GRANDEURY, Klaus-Peter MOLL, Martin MUELLER-ZSIGMONDY, Karsten PUTZBACH, Dirk SPICKERMANN, Hubert THOMA, Mike UFER
  • NMDA receptor modulators and uses thereof
    Patent number: 11807650
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: November 7, 2023
    Assignee: Novartis AG
    Inventors: David R. Anderson, Robert Volkmann, Frank Menniti, Christopher Fanger, Yuelian Xu
  • Selection vectors and methods of selecting eukaryotic host cells
    Patent number: 11807855
    Abstract: The disclosure is directed to an expression vector or a combination of at least two expression vectors for producing a polypeptide of interest, the vector or vectors comprising a polynucleotide encoding a mutated folate receptor as a selectable marker. The disclosure also relates to host cells, selection methods and methods for producing polypeptides with high yield.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: November 7, 2023
    Assignee: Novartis AG
    Inventors: Yehuda G Assaraf, Thomas Jostock, Hans-Peter Knopf
  • Methods of treating FGF21-associated disorders
    Patent number: 11802152
    Abstract: The present invention relates to monoclonal antibodies and antigen-binding fragments thereof that bind to human ?-klotho, and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: December 1, 2021
    Date of Patent: October 31, 2023
    Assignee: Novartis AG
    Inventors: Brian Boettcher, Shari Lynn Caplan, Regis Cebe, Guochun Li, John A. Taraszka, Fangmin Xu, David Langdon Yowe
  • Pharmaceutical products and stable liquid compositions of IL-17 antibodies
    Patent number: 11801300
    Abstract: The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: October 31, 2023
    Assignee: NOVARTIS AG
    Inventors: Susanne Joerg, Kathrin Serno-Schersch
  • Pyrazolopyridine derivatives and uses thereof
    Patent number: 11787785
    Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: October 17, 2023
    Assignee: NOVARTIS AG
    Inventors: Simone Bonazzi, Artiom Cernijenko, Jennifer Stroka Cobb, Natalie Alysia Dales, Janetta Dewhurst, Matthew James Hesse, Rama Jain, John Ryan Kerrigan, Hasnain Ahmed Malik, James R. Manning, Gary O'Brien, Andrew W. Patterson, Noel Marie-France Thomsen, Pamela Y F Ting
  • Sacubitril calcium salts
    Patent number: 11786498
    Abstract: The invention relates to polymorphic forms of the calcium salt of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester. The calcium salt of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester is useful in the treatment of various conditions and disorders responsive to the inhibition of neutral endopeptidases.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: October 17, 2023
    Assignee: Novartis AG
    Inventors: David Hook, Bin Hu, Florian Karl Kleinbeck, Ulrich Meier, Sibylle Mueller, Jean-Paul Mutz, Jan Schlomach, Paul Allen Sutton, Liladhar Murlidhar Waykole, Bernhard Wietfeld